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Abstract
A strategy for introducing structural diversity into polyketides by exploiting the promiscuity of an 
in-line methyltransferase domain in a multidomain polyketide synthase in reported. In vitro 
investigations using the highly-reducing fungal polyketide synthase CazF revealed that its 
methyltransferase domain accepts the nonnatural cofactor propargylic Se-adenosyl-L-methionine 
and can transfer the propargyl moiety onto its growing polyketide chain. This propargylated 
polyketide product can then be further chain-extended and cyclized to form propargyl-α pyrone, or 
be processed fully into the alkyne-containing 4′-propargyl-chaetoviridin A.
S-Adenosyl-L-methionine (SAM, 1)-dependent methyltransferases are a highly versatile 
class of enzymes that catalyze the methylation of DNA, RNA, protein and small molecules 
using the sulfonium methyl group of 1.1 Remarkably, these enzymes have been shown to 
accept synthetic SAM analogues and can catalyze the transalkylation of their corresponding 
proteins,2 nucleic acids3 and small molecules4 substrates with reactive bioorthogonal 
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functional groups. In addition to freestanding methyltransferases, methyltranserase (MT) 
domains can also be found within polyketide synthases (PKS) where they catalyze the α-
methylation of a growing β-keto polyketide chain using 1 as the methyl-donating cofactor.5
Polyketide natural products are a structurally diverse class of molecules isolated from 
bacteria, fungi and plants and represent a rich source of medicinally important compounds.6 
The complex structures associated with polyketides arise from the utilization of simple 
building blocks, such as malonyl-CoA, and can undergo varying degrees of β-keto reduction 
during each catalytic cycle on the PKS.7 As a result, enzyme-directed engineering 
approaches have been aimed at diversifying building block and starter unit selection as a 
way to enhance the structural variation of polyketides and to create analogues containing 
nonnative functional groups.8 Recently, enzyme engineering efforts with bacterial 
acyltransferase (AT) domains9 and acyl-CoA synthetases10 have been successful at 
assimilating nonnatural moieties into polyketides using synthetic malonic acid building 
blocks. While these synthetic biology strategies are promising for enhancing the structural 
diversity of polyketides, an alternative method for introducing structural variation can 
involve the use of nonnatural cofactors. Thus, given the reported promiscuous nature of 
standalone methyltransferases, we wanted to investigate whether MT domains found within 
PKSs could behave in the same manner and facilitate the incorporation of different alkyl 
groups at the α-positions of polyketides.
To examine the substrate specificity of a PKS MT domain, we turned our attention to the 
fungal highly-reducing PKS (HR-PKS) CazF, which is involved in the biosynthesis of the 
chaetoviridin and chaetomugilin azaphilones.11 In vitro reconstitution experiments with 
recombinant CazF (284 kDa) expressed from Saccharomyces cerevisiae BJ5464-NpgA12 
verified that the MT domain functions after the first chain-extending condensation step 
(Figure 1), and the remaining domains are all catalytically active to generate a small 
polyketide product.11 CazF therefore represented a good model system for exploring 
whether a MT domain can be used to introduce chemical diversity into polyketides. We 
selected the two unnatural SAM analogues propargylic Se-adenosyl-L-methionine 
(ProSeAM, 2)2d, 2h and keto-SAM (3)2d,13 for this study because both analogs can provide a 
reactive handle that can be further modified with mild, orthogonal chemistry. The selenium 
containing 2 was selected over the sulfur-based propargylic SAM derivative because it is 
more stable at physiological pH with a half-life of approximately one hour.2d
We first assayed the kinetics of the CazF MT domain towards the unnatural cofactors. 
Recombinant CazF was incubated with acetoacetyl-S-N-acetyl cysteamine (acetoacetyl-
SNAC, 4) in the presence of 1, 2, or 3 (Scheme 1). The production of alkylated acetoacetyl-
SNAC products were analyzed by liquid chromatography and mass spectroscopy (LC-MS); 
and kinetic constants were calculated by fitting initial velocity data at various concentrations 
of 1 or 2 to Michaelis-Menten parameters using nonlinear least squares curve fitting. In the 
assays containing 3, no product was detected suggesting that the MT domain would not 
accept the ketone derivative. The alkylated 5 and 6 were formed in the presence of 1 and 2, 
respectively. The steady-state kinetic parameters were kcat = 0.025 min−1 and KM = 15.5 μM 
for 1; and kcat = 0.036 min−1 and KM = 43.6 μM for 2. Although the turnover rates were 
slow for both 1 and 2, the comparable kinetic parameters indicate that the CazF MT displays 
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similar preference towards 1 and 2. The slow turnover rate may be attributed to the use of a 
small molecule SNAC-bound substrate instead of an acyl-carrier protein (ACP)-tethered 
molecule.
After confirming that the MT domain would accept 2 and transfer the propargyl moiety onto 
4, we assessed whether the β-ketoacyl synthase (KS) domain of CazF would accept the 
propargylated-diketide intermediate and perform another decarboxylative Claisen 
condensation reaction with malonyl-CoA to form the propargylated triketide product. 
Previous in vitro characterization assays with CazF demonstrated that the enzyme can 
produce the triacetic acid lactone 7 when incubated with only malonyl-CoA, and the 
dimethylated α-pyrone 8 when SAM was included in the reaction (Figure 1).11 To determine 
whether CazF could produce a propargyl-α-lactone, the enzyme was incubated with 
malonyl-CoA and 0.2 mM of 2. Following incubation, the reaction mixture was treated with 
1 M NaOH (base hydrolysis) and the organic extract was analyzed by LC-MS. Production of 
the propargylated-α-pyrone 9 was observed verifying that the KS domain can indeed 
tolerate the bulkier propargyl substituent in the diketide and extend it to the corresponding 
triketide product (Figure 1).14 To confirm the structure of 9 synthesized by CazF, a synthetic 
standard was prepared using a 4-step sequence (Scheme 2).15 Alkylation of commercially 
available 2,4-pentanedione with 3-bromoprop-1-yn-1-yl-trimethylsilane provided the dione 
10, which in turn, was elaborated to the β,δ-diketoester 11 using sodium 
bis(trimethylsilyl)amide and dimethyl carbonate. A base-mediated cyclization of 11 with 
DBU yielded pyrone 12, which underwent alkyne deprotection to furnish 9.
The higher amount of des-methylated compound 7 observed in the assay using 2 instead of 1 
does suggest that under the reaction conditions, the rate of MT-alkylation is slower with the 
unnatural cofactor, and that the KS was able to outcompete the MT domain in extending the 
chain without alkylation. With the natural cofactor 1, MT-catalyzed methylation is faster, 
which results in 8 as the dominant product. Increasing the concentration of 2 to 1 mM did 
not alter the ratio of 9 and 7, which was expected since the KM towards 2 was measured to 
be <50 μM.
Previous in vitro reconstitution experiments established that when 1, along with NADPH 
used by the KR domain are present, the triketide product 13 is synthesized by CazF and is 
transacylated by the acyltransferase CazE to the pyranoquinone intermediate 
cazisochromene (14) to form chaetoviridin A (15) (Scheme 3).11 To further explore the 
tolerance of PKS domains, such as that of the KR towards the propargylated diketide and 
post-PKS accessory enzyme CazE towards the propargyl-containing polyketide intermediate 
16, we tested whether an alkyne- containing analog of 15, such as 17, can be synthesized 
using the same set of enzymes. Equimolar amounts of CazF and CazE were incubated with 
14, NADPH, malonyl-CoA and 2. LC-MS analysis of the organic extract revealed the 
formation of a new product with a shorter retention time than 15 and a [M+H]+ m/z = 457 
(Figure 2A) consistent with that of 17. This new compound has an identical UV profile to 15 
and an isotopic mass ratio consistent with the presence of one chlorine atom. Based on these 
observations, we assigned the product to be 4′ propargyl-chaetoviridin A (17). To provide 
additional evidence towards the identify of the new product, a Cu(I)-catalyzed azide-alkyne 
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Huisgen cycloaddition reaction16 was performed to verify if 17 did indeed contain a 
terminal alkyne moiety. After reacting the organic extract containing 17 with azide-
PEG3-5(6)- carboxytetramethylrhodamine, formation of a new peak 18 together with the 
disappearance of 17 was detected by LC-MS (Figure 2B). This new product exhibited UV 
absorption λmax at 550 nm, which is charcteristic of the rhodamine dye; and a [M+H]+ m/z = 
1087, which is identical to the expected mass of the triazole-containing molecule 18 that 
forms as a result of alkyne mediated cycloaddition. Taken together, our experiments show 
that the propargyl functionality installed by the MT domain can indeed be propagated 
throughout the downstream reaction steps, and be found in the final natural product analog.
In summary, we demonstrated that the auxiliary MT domain within the highly-reducing 
fungal PKS CazF can act as a gateway for introducing orthogonally reactive functional 
groups into polyketides. Using the promiscuous nature of the MT domain, our study unveils 
an alternative approach for enhancing the structural diversity of natural products and opens 
the door for accessing and exploiting MT domains in other natural product systems.
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α-pyrones 7–9 biosynthesized by CazF in the presence of (i) malonyl-CoA and SAM 1 or 
(ii) malonyl-CoA and ProSeAM 2. HPLC traces are shown in the same scale at λ= 280 nm. 
Domain organization of CazF consists of a ketosynthase (KS), malonyl-CoA:ACP 
acyltransferase (MAT), dehydratase (DH), methyltransferase (MT), enoyl reductase (ER) 
ketoreductase (KR) and acyl carrier protein (ACP).
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Analysis of the enzymatically synthesized chaetoviridins. A) HPLC analysis (360 nm) of 
chaetoviridins biosynthesized in vitro when (i) CazF and CazE were incubated with 14, 
malonyl-CoA, NADPH and 1 and (ii) CazF and CazE were incubated with 14, malonyl-
CoA, NADPH and 2. B) HPLC analysis (550 nM) of the triazole-containing 18 after 
labeling 17 with the rhodamine-azide.
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CazF-mediated transalkylation of 4 using its natural cofactor 1 or unnatural analogues 2 or 3 
as the alkyl donor
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Synthesis of 9 using 2,4-pentanedione and (3-bromoprop-1-yn-1-yl)trimethylsilane15
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Biosynthesis of chaetoviridin A (15) and 4′-propargyl-chaetoviridin A (17) using the HR-
PKS CazF, the acyltransferase CazE and the caz pyrano-quinone intermediate 
cazisochromene (14) in the presence of the alkylating cofactor 1 or 2.
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